Commentary

High-density Lipoproteins (HDLs): Biomarkers or bio-actors of abdominal aortic aneurysmal disease?

Olivier Meilhac a,b

a Université de La Réunion, Inserm, UMR 1188 Diabète athérosclérose Thérapies Réunion Océan Indien (DéTROI), Plateforme CYROI, 2 rue Maxime Rivière 97490 Sainte-Clotilde, Réunion, France
b CHU de La Réunion, Allée des Topazes, 97400 Saint-Denis, Réunion, France

1. Limits of HDL-C as factor preventing cardiovascular diseases

High-density lipoproteins (HDLs) are characterized by their ability to carry out reverse transport of cholesterol from peripheral tissues back to the liver. HDL-cholesterol (HDL-C) concentration has been known for a long time to be inversely correlated with cardiovascular diseases. However, an increasing body of evidence suggests that circulating HDL-C levels may only represent a surrogate marker of atherosclerosis and that these lipoproteins do not participate in the etiology of cardiovascular disease. In fact, Mendelian randomization studies did not support a clear demonstration. However, in later stages of this disease, the role of lipid accumulation in the first steps of aortic atheroma, that constitutes the substrate for the formation of an intraluminal thrombus, is clearly demonstrated. However, in later stages of this disease, the role of lipids is not established. Therefore, in this context, the relevance of testing HDL function as a mediator for reverse transport of cholesterol is questionable. Indeed, HDLs display pleiotropic effects including anti-oxidant, anti-inflammatory or anti-protease properties (such as anti-oxidase) that may prevent the development of AAA pathology [4]. In their study, Martinez-Lopez et al. have shown that apoA1 post-translational modifications are mediated, at least in part, by polymorphonuclear neutrophils (PMNs). PMNs are the most abundant class of leukocytes but are often underestimated in atherogenesis and atherothrombotic complications in favor of lymphocytes. PMNs, particularly abundant in the luminal thrombus of AAA, are likely to be a source of oxidative and proteolytic enzymes that may produce specific biomarkers reflecting their activation. Martin-Lopez et al. could not test the function of HDLs isolated from AAA tissue and the mass spectrometry technique used did not allow them to assess potential proteolytic modifications of HDL-associated proteins (due to the digestion by trypsin prior to MS analysis). This study raises the question of the origin of exacerbated neutrophil activation during the course of AAA pathogenesis. Different triggers may activate PMNs, such as chronic bacterial exposure (i.e. periodontal bacteria [5]).

2. Abdominal aortic aneurysm (AAA): an atherothrombotic complication or a lipid-free aortic dilatation?

There is still controversy as to whether AAAs may be considered or not as the result of advanced atherosclerosis of the aortic wall [3]. The role of lipid accumulation in the first steps of aortic atheroma, that constitutes the substrate for the formation of an intraluminal thrombus, is clearly demonstrated. However, in later stages of this disease, the role of lipids is not established. Therefore, in this context, the relevance of testing HDL function as a mediator for reverse transport of cholesterol

DOI of original article: https://doi.org/10.1016/j.ebiom.2019.04.012.

E-mail address: olivier.meilhac@insERM.fr.

3. A future for HDL in AAA?

Whereas pharmacological increases in HDL-C have failed to prevent cardiovascular disease, repeated supplementation with functional HDL may represent a potential therapy able to limit the expansion of the thrombus in AAA pathology, as demonstrated in a pre-clinical study [6]. To date, HDL infusion in humans has only been tested in atheromatosus and diabetic conditions, taking advantage of the ability of HDL to reduce cholesterol levels and to protect the endothelium [7]. HDL-based therapy for AAA may represent an option for limiting AAA growth, taking advantage of their pleiotropic effect that may allow tissue healing.

The search for biomarkers in the field of AAA has attracted much attention; they should be able either to detect the disease itself or to reflect its progression. The study by Martinez-Lopez et al. revealed that HDL-associated apoA1 is oxidized on Trp residues, potentially due to the activation of neutrophils that release reactive oxygen species and pro-oxidant enzymes, leading to the production of dysfunctional HDL particles. Whereas HDL function may be difficult to evaluate in routine clinical practice, oxidative modification of apoA1 may be more easily quantifiable using antibodies directed against specific epitopes. In addition, proteins other than apoA1 contained in the AAA thrombus
probably also undergo such oxidative modifications. Further studies investigating the “proteoxidome” contained within the AAA thrombus, and potentially diffusing into the bloodstream, are necessary to unveil new biomarkers of AAA disease and of its progression.

Disclosure

Dr. Meilhac has nothing to disclose.

References

[1] Barter P, Genest J. HDL cholesterol and ASCVD risk stratification: a debate. Atherosclerosis 2019;283:7–12.

[2] Martinez-Lopez D, Camafeita E, Cedoc L, et al. APOA1 oxidation is associated to dysfunctional high-density lipoproteins in human abdominal aortic aneurysm; 2019. https://doi.org/10.1016/j.atherosclerosis.2019.04.012.

[3] Nordon IM, Hinchcliffe RJ, Holt PJ, Loftus IM, Thompson MM. Review of current theories for abdominal aortic aneurysm pathogenesis. Vascular 2009;17(5):253–63.

[4] Ortiz-Munoz C, Houard X, Martin-Ventura JL, et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009;23(9):3129–39.

[5] Delbosc S, Alsac JM, Journe C, et al. Porphyromonas gingivalis participates in pathogenesis of human abdominal aortic aneurysm by neutrophil activation. Proof of concept in rats. PLoS One 2013;8(6):e61867.

[6] Delbosc S, Rouer M, Alsac JM, et al. High-density lipoprotein therapy inhibits Porphyromonas gingivalis-induced abdominal aortic aneurysm progression. Thromb Haemost 2016;115(4):789–99.

[7] Tran-Dinh A, Biallo D, Delbosc S, et al. HDL and endothelial protection. Br J Pharmacol 2013;169(3):493–511.